WO2008043072A3 - Cd80 antagonists for treating neoplastic disorders - Google Patents

Cd80 antagonists for treating neoplastic disorders Download PDF

Info

Publication number
WO2008043072A3
WO2008043072A3 PCT/US2007/080590 US2007080590W WO2008043072A3 WO 2008043072 A3 WO2008043072 A3 WO 2008043072A3 US 2007080590 W US2007080590 W US 2007080590W WO 2008043072 A3 WO2008043072 A3 WO 2008043072A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
neoplastic disorders
treating neoplastic
compositions
disorders
Prior art date
Application number
PCT/US2007/080590
Other languages
French (fr)
Other versions
WO2008043072A2 (en
Inventor
Faheem Hasnain
Kandasamy Hariharan
Steffan Ho
Shabnam Tangri
Original Assignee
Biogen Idec Inc
Faheem Hasnain
Kandasamy Hariharan
Steffan Ho
Shabnam Tangri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Faheem Hasnain, Kandasamy Hariharan, Steffan Ho, Shabnam Tangri filed Critical Biogen Idec Inc
Publication of WO2008043072A2 publication Critical patent/WO2008043072A2/en
Publication of WO2008043072A3 publication Critical patent/WO2008043072A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds

Abstract

Compositions comprising a heterocyclic compound and methods of using these compositions, alone or in combination with a second therapeutic agent, are provided for treating diseases or disorders in which CD80-expressing cells or regulatory T cell function contribute to or exacerbate the associated pathology. The disclosed combination therapies result in synergistic anti-tumor responses.
PCT/US2007/080590 2006-10-05 2007-10-05 Cd80 antagonists for treating neoplastic disorders WO2008043072A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53915306A 2006-10-05 2006-10-05
US11/539,153 2006-10-05
US90864507P 2007-03-28 2007-03-28
US60/908,645 2007-03-28

Publications (2)

Publication Number Publication Date
WO2008043072A2 WO2008043072A2 (en) 2008-04-10
WO2008043072A3 true WO2008043072A3 (en) 2008-12-18

Family

ID=39269251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080590 WO2008043072A2 (en) 2006-10-05 2007-10-05 Cd80 antagonists for treating neoplastic disorders

Country Status (1)

Country Link
WO (1) WO2008043072A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. Therapeutic cd47 antibodies
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048378A1 (en) * 2002-11-22 2004-06-10 Active Biotech Ab Pyrazoloquinolines with immunomodulating activity
US6896885B2 (en) * 2000-03-31 2005-05-24 Biogen Idec Inc. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896885B2 (en) * 2000-03-31 2005-05-24 Biogen Idec Inc. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
WO2004048378A1 (en) * 2002-11-22 2004-06-10 Active Biotech Ab Pyrazoloquinolines with immunomodulating activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUXLEY P. ET AL.: "High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy", CHEMISTRY & BIOLOGY, vol. 11, December 2004 (2004-12-01), pages 1651 - 1658, XP004689689 *
SUVA S. ET AL.: "Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma", J. BIOL. CHEM., vol. 277, no. 10, March 2002 (2002-03-01), pages 7766 - 7775, XP002490051 *

Also Published As

Publication number Publication date
WO2008043072A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
MX2009013332A (en) Ire-1a inhibitors.
WO2011127070A3 (en) IRE-1α INHIBITORS
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2009086471A3 (en) Synergistic antiparasitic compositions and screening methods
EA200901486A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2009081105A3 (en) Quinoxaline and quinoline derivatives as kinase inhibitors
WO2010065491A3 (en) Methods of treating inflammatory disorders
IL209927A (en) Sulfur-containing heterocyclic derivatives, compositions comprising them and uses thereof in the manufacture of medicaments for inhibiting beta secretase activity
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
SI2374472T1 (en) Compositions and methods for treating ophthalmic disorders
WO2010038086A3 (en) P38 map kinase inhibitors
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
SI2176252T1 (en) 2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007150046A3 (en) Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853795

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07853795

Country of ref document: EP

Kind code of ref document: A2